Next Article in Journal
The In Vitro and In Vivo Anti-Inflammatory Effects of a Phthalimide PPAR-γ Agonist
Next Article in Special Issue
Biochemical and Structural Insights into a Novel Thermostable β-1,3-Galactosidase from Marinomonas sp. BSi20414
Previous Article in Journal
Structure-Based Design and Synthesis of a New Phenylboronic-Modified Affinity Medium for Metalloprotease Purification
Previous Article in Special Issue
Novel Peptide with Specific Calcium-Binding Capacity from Schizochytrium sp. Protein Hydrolysates and Calcium Bioavailability in Caco-2 Cells
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessArticle
Mar. Drugs 2017, 15(1), 8; doi:10.3390/md15010008

In vitro Anti-Thrombotic Activity of Extracts from Blacklip Abalone (Haliotis rubra) Processing Waste

1
School of Medicine, The University of Queensland, Translational Research Institute, Kent Street, Woolloongabba 4102, Australia
2
CSIRO Agriculture, 306 Carmody Road, St Lucia 4067, Australia
*
Authors to whom correspondence should be addressed.
Academic Editor: Se-Kwon Kim
Received: 17 November 2016 / Revised: 22 December 2016 / Accepted: 28 December 2016 / Published: 31 December 2016
(This article belongs to the Special Issue Marine Proteins and Peptides)
View Full-Text   |   Download PDF [1462 KB, uploaded 31 December 2016]   |  

Abstract

Waste generated from the processing of marine organisms for food represents an underutilized resource that has the potential to provide bioactive molecules with pharmaceutical applications. Some of these molecules have known anti-thrombotic and anti-coagulant activities and are being investigated as alternatives to common anti-thrombotic drugs, like heparin and warfarin that have serious side effects. In the current study, extracts prepared from blacklip abalone (Haliotis rubra) processing waste, using food grade enzymes papain and bromelain, were found to contain sulphated polysaccharide with anti-thrombotic activity. Extracts were found to be enriched with sulphated polysaccharides and assessed for anti-thrombotic activity in vitro through heparin cofactor-II (HCII)-mediated inhibition of thrombin. More than 60% thrombin inhibition was observed in response to 100 μg/mL sulphated polysaccharides. Anti-thrombotic potential was further assessed as anti-coagulant activity in plasma and blood, using prothrombin time (PT), activated partial thromboplastin time (aPTT), and thromboelastography (TEG). All abalone extracts had significant activity compared with saline control. Anion exchange chromatography was used to separate extracts into fractions with enhanced anti-thrombotic activity, improving HCII-mediated thrombin inhibition, PT and aPTT almost 2-fold. Overall this study identifies an alternative source of anti-thrombotic molecules that can be easily processed offering alternatives to current anti-thrombotic agents like heparin. View Full-Text
Keywords: blacklip abalone; processing waste; bioactive molecules; anti-thrombotic activity blacklip abalone; processing waste; bioactive molecules; anti-thrombotic activity
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Suleria, H.A.R.; Hines, B.M.; Addepalli, R.; Chen, W.; Masci, P.; Gobe, G.; Osborne, S.A. In vitro Anti-Thrombotic Activity of Extracts from Blacklip Abalone (Haliotis rubra) Processing Waste. Mar. Drugs 2017, 15, 8.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top